Frederick, MD — Gov. Wes Moore on Friday announced that AstraZeneca will invest $2 billion to expand its operations in Maryland in what he described as the “single largest private investment in ...

DEVELOPMENTS FROM FREDERICK. THE INVESTMENT PROVIDES AN ECONOMIC SHOT IN THE ARM, CREATES JOBS AND BOOSTS THE STATE’S EFFORT TO EXPAND MARYLAND’S LIFE SCIENCES SECTOR. TODAY IS ABOUT SHOWING THAT WE ...

The pharmaceutical giant is plowing billions of dollars into expanding its drug-making capacity. It has ambitious plans for two facilities in Maryland. AstraZeneca announced it is investing $2 billion ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The expansion, which follows a ...

The lawsuits allege gross negligence and reckless disregard for safety. The families of multiple campers and two counselors at Camp Mystic who died in the devastating flash flood in Texas in July are ...

The pharmaceutical sector mainstay reported good news about its developmental hypertension drug. It purchased the medicine's maker, CinCor Pharma, in early 2023. Early this morning, AstraZeneca shared ...

MANSFIELD, La. – Former District Attorney Gary Evans has settled two lawsuits filed by the DeSoto Clerk of Court’s Office. Evans, represented in DeSoto District Court last week by his brother, ...

The Ethiopian Air Flight 302 crash in 2019 was the second involving a Boeing 737 Max 8, which was later grounded. The three settled cases against Boeing were brought by Clifford Law Offices, while ...

Boeing (BA) reached confidential settlements in three lawsuits filed by families of passengers killed in the 2019 Ethiopian Airlines Flight 302 disaster, the victims’ attorney said on Wednesday. The ...

AstraZeneca Plc’s profit rose more than analysts anticipated last quarter, buoyed by demand for its blockbuster cancer and diabetes drugs. Earnings per share, excluding some items, climbed 14% to ...

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a phase 2 study. The U.K.-based pharma had been evaluating the antisense ...